Individuals with Medicaid or no health insurance have 3.12 and 2.21 times greater odds, respectively, of being diagnosed with late-stage melanoma. »
06/15/19
Olaparib is approved as maintenance therapy in patients with BRCA mutated platinum sensitive (PS) recurrent ovarian cancer (OC) after response to last platinum based therapy. Few data are available regarding the use out of the registration trials and on response to further treatments after progression. »
08/05/19